When celecoxib enters the body alongside lithium, something dangerous happens: lithium plasma levels surge by approximately 17% on average. That single statistic represents a major severity interaction flagged in FDA drug labeling—one that healthcare providers and patients cannot afford to overlook.
Lithium, the gold-standard mood stabilizer for bipolar disorder, operates within a narrow therapeutic window. A 17% elevation is not a minor fluctuation. It's the difference between symptom control and lithium toxicity. For millions of Americans managing bipolar disorder, rheumatoid arthritis, or osteoarthritis simultaneously, this interaction represents a critical safety challenge that requires vigilant monitoring and informed decision-making.
According to FDA drug labeling for celecoxib, patients on stable lithium therapy experience measurable increases in steady-state lithium plasma concentrations when celecoxib is introduced. The mechanism is straightforward but consequential: celecoxib, a selective COX-2 inhibitor (NSAID), reduces renal lithium clearance, causing the drug to accumulate in the bloodstream.
This is classified as a major severity interaction by the U.S. FDA, placing it among the highest-risk drug combinations. Major interactions carry the potential for serious adverse effects, hospitalization, or worsening of existing conditions. In the case of celecoxib and lithium, that translates directly to lithium toxicity risk.
Lithium toxicity symptoms include:
Patients and providers managing both conditions face a real-world dilemma: how to control pain or inflammation without sacrificing psychiatric stability.
NSAIDs like celecoxib inhibit prostaglandin synthesis in the kidneys. Prostaglandins play a critical role in maintaining renal blood flow and glomerular filtration. When prostaglandin production drops, renal function changes—and lithium, which is filtered passively by the kidneys and not metabolized by the liver, begins to accumulate.
Celecoxib is a selective COX-2 inhibitor, originally developed to reduce GI side effects compared to nonselective NSAIDs. However, this selectivity provides no protection against the lithium interaction. The FDA label for celecoxib explicitly warns that lithium monitoring is necessary, whether celecoxib is introduced to an existing regimen or withdrawn from one.
The 17% mean increase in steady-state plasma levels isn't uniform across all patients. Individual factors affect the magnitude of interaction:
Some patients may experience larger increases; others, smaller ones. This variability underscores why monitoring isn't optional—it's essential.
The U.S. FDA label for celecoxib contains explicit warnings about lithium co-administration. The guidance is clear: patients on lithium should be closely monitored when celecoxib is introduced or withdrawn.
Clinical monitoring should include:
Lithium has a therapeutic window typically between 0.6–1.2 mEq/L. A 17% increase on a level of 0.9 mEq/L raises it to approximately 1.05 mEq/L—still technically therapeutic, but pushing toward the upper limit. For patients already near the therapeutic ceiling, the same 17% increase could cross into toxicity.
When patients require both psychiatric stability (lithium) and pain or anti-inflammatory management, several approaches are available:
Never adjust lithium dose preemptively in anticipation of celecoxib use. Lithium dosing should be guided by measured serum levels, not assumptions.
If you take lithium and are prescribed celecoxib, your healthcare team must communicate. Your pharmacist should flag this interaction at the point of dispensing. Your physician should confirm awareness and establish a monitoring protocol before you fill the prescription.
Ask your provider:
The 17% increase in lithium plasma levels caused by celecoxib is not theoretical—it's documented in FDA labeling and supported by clinical evidence. This major severity interaction demands respect, but it need not be insurmountable. Informed decision-making, transparent communication between patient and provider, and systematic monitoring make safe co-prescription possible.
Your safety depends on awareness. Make sure your entire healthcare team knows every medication you take, especially lithium. Before starting celecoxib or any new medication, always verify interactions with your pharmacist.
To check for interactions between celecoxib, lithium, and any other medications you take, visit checkdruginteractions.com—the most comprehensive drug interaction checker on the internet, with over 250,000 FDA-labeled drug records.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.